Whilst I wait for Dame Emma and her GSK plc conference call, thoughts on the continued Aston Martin Lagonda comedy and Next plc commonsense
By Chris Bailey | Wednesday 2 November 2022
Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
I always analytically like the pharmaceutical sector, even if I am not enough of a sector geek to be a massive expert. It is getting close to two years since I bought GSK plc (GSK) shares for the first time in a couple of decades. It gave a solid Q3 set of numbers earlier today, talking about “2022 Guidance raised…(as it) expect to deliver growth in sales of between 8%-10% CER and growth in 2022 adjusted operating profit of between 15%-17% CER". It is always better to raise numbers than not, but that does not mean that the management, led by the extremely well remunerated Dame Emma, does not still have a bunch of questions to answer.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism
Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.